Liquid formulation comprising Cetuximab and a polyoxyethylene sorbitan fatty acid ester

The invention relates to a stable liquid pharmaceutical formulation comprising Cetuximab(R), a chimeric monoclonal antibody against the receptor of endothelial growth factor (EGF receptor). The formulation has increased storage stability and can be used parenterally for the treatment of tumours.

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	HANNSRISTIAN MAHLER, ULRIKE MARTINI-MARR, CHRISTIANE BACHMANN, ROBERT MUELLER, UDO HAAS
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention relates to a stable liquid pharmaceutical formulation comprising Cetuximab(R), a chimeric monoclonal antibody against the receptor of endothelial growth factor (EGF receptor). The formulation has increased storage stability and can be used parenterally for the treatment of tumours.